Identification and characterization of conserved and variable regions in the envelope gene of HTLV-III/LAV, the retrovirus of AIDS.
about
Few and far between: how HIV may be evading antibody avidityCloning, sequence analysis, and expression of the large subunit of the human lymphocyte activation antigen 4F2Pathogenesis of human immunodeficiency virus infectionStructural definition of a conserved neutralization epitope on HIV-1 gp120An algorithm for mapping positively selected members of quasispecies-type viruses.HIV-1 neutralizing antibodies: understanding nature's pathwaysNovel approaches to inhibit HIV entryCrystal structure, conformational fixation and entry-related interactions of mature ligand-free HIV-1 EnvX-Ray Crystal Structures of Human Immunodeficiency Virus Type 1 Protease Mutants Complexed with AtazanavirStructural Basis of Immune Evasion at the Site of CD4 Attachment on HIV-1 gp120Crystal Structure of the HIV-2 Neutralizing Fab Fragment 7C8 with High Specificity to the V3 Region of gp125Structure-Based Design, Synthesis, and Characterization of Dual Hotspot Small-Molecule HIV-1 Entry InhibitorsStructural Basis for Enhanced HIV-1 Neutralization by a Dimeric Immunoglobulin G Form of the Glycan-Recognizing Antibody 2G12Structure of an HIV gp120 envelope glycoprotein in complex with the CD4 receptor and a neutralizing human antibodyPotent and selective inhibition of human immunodeficiency virus (HIV)-1 and HIV-2 replication by a class of bicyclams interacting with a viral uncoating eventNew tetrahydroimidazo[4,5,1-jk][1,4]-benzodiazepin-2(1H)-one and -thione derivatives are potent inhibitors of human immunodeficiency virus type 1 replication and are synergistic with 2',3'-dideoxynucleoside analogsU-90152, a potent inhibitor of human immunodeficiency virus type 1 replicationThe evolutionary analysis of emerging low frequency HIV-1 CXCR4 using variants through time--an ultra-deep approachHIV-1 Env C2-V4 diversification in a slow-progressor infant reveals a flat but rugged fitness landscapeHuman antibodies that neutralize HIV-1: identification, structures, and B cell ontogeniesNonrandom distribution of gp120 N-linked glycosylation sites important for infectivity of human immunodeficiency virus type 1Characterization of the fusion domain of the human immunodeficiency virus type 1 envelope glycoprotein gp41What Are the Most Powerful Immunogen Design Vaccine Strategies?Human monoclonal antibody 2G12 defines a distinctive neutralization epitope on the gp120 glycoprotein of human immunodeficiency virus type 1Lower in vivo mutation rate of human immunodeficiency virus type 1 than that predicted from the fidelity of purified reverse transcriptaseSurvivors Remorse: antibody-mediated protection against HIV-1.Recent advances on the use of structural biology for the design of novel envelope immunogens of HIV-1Computer-assisted analysis of envelope protein sequences of seven human immunodeficiency virus isolates: prediction of antigenic epitopes in conserved and variable regions.HIV-1 envelope subregion length variation during disease progressionC-terminal tail of human immunodeficiency virus gp41: functionally rich and structurally enigmatic.Matrix-assisted laser desorption ionization/mass spectrometry mapping of human immunodeficiency virus-gp120 epitopes recognized by a limited polyclonal antibody.HIV-1 and influenza antibodies: seeing antigens in new waysType-specific neutralization of the human immunodeficiency virus with antibodies to env-encoded synthetic peptides.Antibodies that inhibit fusion of human immunodeficiency virus-infected cells bind a 24-amino acid sequence of the viral envelope, gp120The N-terminal region of the human immunodeficiency virus envelope glycoprotein gp120 contains potential binding sites for CD4.High levels of heterodisperse RNAs accumulate in T cells infected with human immunodeficiency virus and in normal thymocytes.A non-canonical binding interface in the crystal structure of HIV-1 gp120 core in complex with CD4Evolutionary origin of human and simian immunodeficiency viruses.Human immunodeficiency virus type 1 challenge of chimpanzees immunized with recombinant envelope glycoprotein gp120HIV-1 envelope determinants for cell tropism and chemokine receptor use.
P2860
Q21090507-6387797F-445C-40B5-A582-F6DB34408749Q24631057-729BFCD7-7527-4D8C-8105-AA71C51BFFB0Q24634681-B930DA48-7D11-46E7-ACE2-67542DAE952CQ24655948-BD533BAC-9D8C-48C3-B00C-2C5E5D812C0BQ24797088-71CAB25B-4660-44EB-937A-C0FA35FE74B8Q27000480-FDB821D4-623E-447F-8E30-932C41E749DAQ27013957-BD11BA16-27BF-4950-AFBD-E85DDA1FD400Q27644383-436DCE20-E8C0-42C1-87AF-A35C5E83A76DQ27645052-2ABD214E-D4DB-4B2F-900A-91D339D1E811Q27658449-DB57BE45-B36C-4B48-92FC-70D7DE37CB48Q27667679-D6B5363C-583A-480D-BD0D-39C8BF1E66B6Q27678493-DA1949EE-0A13-4331-B6C5-F1157E448F00Q27680810-34E1B0D1-767F-44E6-AA70-19A101B5DCCBQ27759364-945DB033-2C64-48CC-BE12-8ECA9850451AQ28320362-B0EAEE23-A487-41CE-972A-0C0D8C30459AQ28367654-079E83B3-FB77-4C8E-8DF5-AFC7BA102160Q28368034-04650D3B-DD34-4186-98B4-155FC9C9B1C1Q28476558-0AFAC83C-B206-460A-9FB0-6998F223A5FEQ28487168-2AAB5820-1273-4A4C-8E9F-A02CAFD23CA2Q28602877-0BDF49E4-613E-499E-BCE0-9B4554538E2BQ28646731-68AA9DAF-5ACE-4BE9-9538-2EB4E6C99233Q28646771-1BBB9979-6B42-41AB-822D-FEBEF1E775F2Q28729792-808B1437-E79B-4C42-84F4-F835A6A12767Q29619512-2D3F3C44-B42D-4B65-829B-9F6838C4EE48Q29619994-8E6EC319-236E-4CCC-854D-7A4B461BA0D6Q30238730-FD513AD4-EEE3-426C-B4E7-64295659DF77Q30353580-DA52B732-5525-401E-8A9D-34F00AF2BF16Q30356755-5DCF1F4A-44C7-4A00-B1A5-22C8C76289F7Q30397933-E6627B72-F6C9-4758-85F6-D51274DBF8D5Q30422545-6AAA86B9-5FAA-4B4E-96DE-EBE768AC9E0BQ32049913-81FC40AA-B2B1-4075-B627-C4EE8387DA01Q33552488-841B5B8F-6995-4EC2-B919-736F3F905843Q33560772-F743F8FA-57C7-4B15-BC3C-C1F5BE9EE1F3Q33571605-0D549020-A16F-48B0-96D3-9287E293BD74Q33579510-790B2D07-4A46-4CA7-BF65-0AE228CB3933Q33582974-345E8FE5-615F-4A8C-86D9-FA5493B4EB94Q33587774-B6A81608-2358-40D2-AD3B-1C60714BC984Q33604826-6724F971-7D27-4D44-A274-860EE7B46F77Q33632668-B4CCEE94-8271-43D0-9EFB-EEC393801947Q33637946-FFFF394B-8508-4E0E-93E6-A89B794297F6
P2860
Identification and characterization of conserved and variable regions in the envelope gene of HTLV-III/LAV, the retrovirus of AIDS.
description
1986 nî lūn-bûn
@nan
1986 թուականի Յունիսին հրատարակուած գիտական յօդուած
@hyw
1986 թվականի հունիսին հրատարակված գիտական հոդված
@hy
1986年の論文
@ja
1986年論文
@yue
1986年論文
@zh-hant
1986年論文
@zh-hk
1986年論文
@zh-mo
1986年論文
@zh-tw
1986年论文
@wuu
name
Identification and characteriz ...... I/LAV, the retrovirus of AIDS.
@ast
Identification and characteriz ...... I/LAV, the retrovirus of AIDS.
@en
type
label
Identification and characteriz ...... I/LAV, the retrovirus of AIDS.
@ast
Identification and characteriz ...... I/LAV, the retrovirus of AIDS.
@en
prefLabel
Identification and characteriz ...... I/LAV, the retrovirus of AIDS.
@ast
Identification and characteriz ...... I/LAV, the retrovirus of AIDS.
@en
P2093
P1433
P1476
Identification and characteriz ...... I/LAV, the retrovirus of AIDS.
@en
P2093
Josephs SF
McNeely PD
Starcich BR
P304
P356
10.1016/0092-8674(86)90778-6
P407
P50
P577
1986-06-01T00:00:00Z